(Q33530405)

27 July 2017

Antimetabolites and cancer: emerging data with a focus on antifolates (English)

1 reference

27 July 2017

1

Giorgio V Scagliotti

1 reference

27 July 2017

Giovanni Selvaggi

2

1 reference

PubMed ID

20144046

27 July 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Therapeutic Patents

27 July 2017

1 reference

27 July 2017

16

1 reference

27 July 2017

2

1 reference

27 July 2017

189-200

1 reference

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

27 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Pharmacogenetics of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Gadolinium texaphyrin-methotrexate conjugates. Towards improved cancer chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Chromosome aberrations in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Pemetrexed (Alimta®): a novel multitargeted antifolate agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Distribution of the novel antifolate pemetrexed to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Nucleoside analogues and nucleobases in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Fatal pulmonary toxicity resulting from treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Antitumor activity of sugar-modified cytosine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Systemic therapy for metastatic colorectal cancer: current options, current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Capecitabine: effective oral fluoropyrimidine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

Role of genomic markers in colorectal cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

The alpha folate receptor is highly activated in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.189

10.1517/13543776.16.2.189

21 January 2018

Identifiers

DOI

1 reference

27 July 2017

1 reference

PubMed ID

20144046